Dual/triple peptide agonists or antagonists Glucose-lowering properties have been attributed not only to GLP-1, but also to GIP and other peptide hormones
While effective, the weight loss achieved with GLP-1s is generally less than that seen with bariatric surgery
A 2021 trial found that NMN supplementation improved muscle insulin sensitivity in prediabetic women, while another study suggested NR supported endothelial function
It is important to remember that not all GLP-1 medications are expressly licensed for weight loss and that the doses used for weight loss may vary from those used for managing diabetes
Prolonged activation of GLP-1, GLP-2, and GIP receptors is achieved through receptor agonists resistant to DPP4 cleavage or through compounds that inhibit DPP4 activity (Jeppesen et al., 2005
They serve different purposes and stack well together in regenerative protocols